Atlas Trials

SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial

Clinical trial NCT07748611 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07748611
Sponsor
Northwestern University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Borderline Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma
Start date
2027-02-03
Primary completion
2030-02-03
Enrollment
125

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.